“ "One of the most significant transformations relates to the regulatory area, with Brazil undoubtedly moving closer to international standards over the past five years." ”
In Conversation
“ "Brazil is the sixth largest pharmaceutical market in the world and we are steadily moving toward the fifth position, which we will probably reach within the… ”
“ "In 2016, Brazil’s overall inflation rate reached 19.8 percent, but the quality of services accessible to our patients is far from increasing at the same pace… ”
“ PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He… ”
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing…
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could…
In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since…
There is little publicly available information on your personal history and the founding of Meizler. Can you share that story for our readers? Everybody has a…
Diabetes affects an estimated 6 million Brazilians, a figure which is expected to double by 2025, in line with many other developing nations. Like many other…
When we interviewed you four years ago, you gave us a picture of the industry. How has that picture changed since then? We can start with…
Hypermarcas is a huge, diversified corporation that sells everything from shampoo, to medicine. Would you consider it more of a consumer goods company that happens to…
Many readers may find it counterintuitive that SINDUSFARMA, which represents syndicates, is organized by a team of management executives. Historically, these two groups tend to be…
